After Revolution Medicines declared its daraxonrasib Phase 3 readout as meeting overall survival and progression-free survival endpoints, Wall Street analysts characterized the result as “unprecedented” and “transformative.” The company said it will treat the interim checkpoint as final, with regulatory filing discussions now moving to the center of the timeline. The trial enrolled patients whose metastatic disease returned after earlier therapy, and Revolution said median survival nearly doubled to 13.2 months versus 6.7 months with chemotherapy. The company also signaled that its FDA voucher status could support approval discussions ahead of a formal submission.